Search Medical Condition
Please enter condition
Please choose location

Pulmonary Arterial Hypertension Clinical Trials

A listing of Pulmonary Arterial Hypertension medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

RESULTS

Found (107) clinical trials

The primary objective of this study is to assess the effect of oral treprostinil compared with placebo on change in exercise capacity as measured by change in 6MWD from Baseline to Week 24 in subjects with PH associated with HFpEF. There are no approved treatments for PH in subjects with ...

Phase

Researchers at the University of Kentucky are conducting a study to investigate the safety and how well the inhaled investigational drug treprostinil works in people with pulmonary hypertension associated with lung disease. This study will look at your ability to exercise after taking the study drug. You may be eligible ...

Phase N/A

NYU Winthrop Hospital Clinical Trials Center is conducting this clinical research study for patients between the ages of 18 and 85 years old, who have been diagnosed with PAH. Pulmonary Arterial Hypertension occurs when the pressure in the pulmonary artery (the blood vessel that leads from the heart to the ...

Phase N/A

People with Pulmonary Arterial Hypertension are asked to participate in a research study being conducted by North Shore University Hospital.

Phase N/A

The Efficacy and Safety of Initial Triple Versus Initial Dual Oral Combination Therapy in Patients With Newly Diagnosed Pulmonary Arterial Hypertension

The objective of this clinical trial is to compare the efficacy and safety of an initial triple oral treatment regimen (macitentan, tadalafil, selexipag) versus an initial dual oral treatment regimen (macitentan, tadalafil, placebo) in newly diagnosed, treatment-nave patients with pulmonary arterial hypertension.

Phase

Riociguat in Children With Pulmonary Arterial Hypertension (PAH)

This study is designed to evaluate the safety, tolerability, pharmacodynamics and pharmacokinetics of riociguat at age-, sex- and body-weight-adjusted doses of 0.5 mg, 1.0 mg, 1.5 mg, 2.0 mg and 2.5 mg TID in children from 6 to less than 18 years with pulmonary arterial hypertension (PAH) group 1. The ...

Phase

ABI-009 an mTOR Inhibitor for Patients With Severe Pulmonary Arterial Hypertension

mTOR activation has been shown to be relevant in the development and progression of pulmonary hypertension. Inhibition of mTOR has been shown to reverse or regress pulmonary hypertension in animal models. ABI-009 is an albumin-bound mTOR inhibitor with improved penetration in lung tissue.

Phase

Bardoxolone Methyl in Patients With Connective Tissue Disease-associated Pulmonary Arterial Hypertension - CATALYST

This double-blind, randomized, placebo-controlled trial will study the safety, tolerability, and efficacy of bardoxolone methyl in qualified patients with WHO Group I CTD-PAH. Qualified patients will be randomized 1:1 to either bardoxolone methyl or placebo to be administered once daily for 24 weeks. Patients randomized to placebo will remain on ...

Phase

A Study to Assess Whether Macitentan Delays Disease Progression in Children With Pulmonary Arterial Hypertension (PAH)

This is a prospective, multicenter, open-label, randomized, controlled, parallel group, group-sequential, event-driven Phase 3 study to evaluate efficacy, safety and pharmacokinetics (PK) of macitentan in children.

Phase

Clinical Study Evaluating the Effects of First-line Oral cOmbination theraPy of maciTentan and tadalafIl in Patients With Newly Diagnosed pulMonary Arterial Hypertension (OPTIMA)

The purpose of the study is to document the effect of first line dual oral combination therapy with macitentan 10mg and tadalafil 40mg on pulmonary vascular resistance (PVR) in treatment-nave patients with newly diagnosed pulmonary arterial hypertension (PAH).

Phase